STUDY TO EVALUATE THE LONG-TERM ANTIBODY PERSISTENCE OF GLAXOSMITHKLINE (GSK) BIOLOGICALS' MENACWY-TT VACCINE (GSK134612) VERSUS MENCEVAX ACWY IN HEALTHY ADOLESCENTS AND ADULTS AND BOOSTER RESPONSE TO MENACWY-TT VACCINE ADMINISTERED AT 10 YEARS POST-PRIMARY VACCINATION: